CD39
CD39
Cancer
conventional CD4+ T cells
cytotoxicity
exhaustion
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
30
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
Conventional CD4
Identifiants
pubmed: 37885970
doi: 10.1080/2162402X.2023.2246319
pii: 2246319
pmc: PMC10599196
doi:
Substances chimiques
CTLA-4 Antigen
0
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2246319Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
E.P. is co-founder of Egle-Tx. E.P. and J.T are consultants for Egle-Tx. The other authors declare no conflicts of interest.
Références
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
J Exp Med. 2007 Jun 11;204(6):1257-65
pubmed: 17502665
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
Nat Med. 2021 May;27(5):820-832
pubmed: 33958794
Nat Rev Immunol. 2019 Nov;19(11):665-674
pubmed: 31570879
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
J Mol Biol. 2021 Jan 8;433(1):166687
pubmed: 33098857
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Eur J Immunol. 2012 Jul;42(7):1876-85
pubmed: 22585562
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Nat Med. 2018 Jul;24(7):986-993
pubmed: 29942092
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Front Immunol. 2017 Oct 31;8:1436
pubmed: 29163509
JCI Insight. 2021 Jan 25;6(2):
pubmed: 33332284
BMC Infect Dis. 2019 Feb 11;19(1):135
pubmed: 30744575
Cancer Immunol Immunother. 2020 Dec;69(12):2599-2611
pubmed: 32591861
Biometrics. 1984 Sep;40(3):601-9
pubmed: 6394063
Clin Cancer Res. 2021 Nov 1;27(21):5742-5752
pubmed: 34127507
Immunity. 2016 Nov 15;45(5):1122-1134
pubmed: 27851913
J Clin Invest. 2011 Jun;121(6):2350-60
pubmed: 21555851
Clin Cancer Res. 2021 Jul 15;27(14):4089-4100
pubmed: 33963000
Cancer Cell. 2022 Apr 11;40(4):393-409.e9
pubmed: 35413271
Cancer Immunol Res. 2013 Oct;1(4):235-44
pubmed: 24396833
Cancer Immunol Res. 2020 Oct;8(10):1311-1321
pubmed: 32759363
Nature. 2019 May;569(7755):270-274
pubmed: 31043744
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
J Exp Med. 1998 Dec 21;188(12):2357-68
pubmed: 9858522
Front Immunol. 2017 Feb 23;8:194
pubmed: 28280496
Eur J Immunol. 2009 Aug;39(8):2076-82
pubmed: 19672903
Bioinformatics. 2018 May 1;34(9):1615-1617
pubmed: 29272348
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
Immunity. 2020 May 19;52(5):825-841.e8
pubmed: 32396847
J Exp Med. 2010 Mar 15;207(3):637-50
pubmed: 20156971
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Front Immunol. 2021 Jul 27;12:713132
pubmed: 34386013
Nature. 2018 Dec;564(7735):268-272
pubmed: 30479382
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
Transl Oncol. 2020 Jan;13(1):17-24
pubmed: 31733591
Curr Opin Immunol. 2022 Feb;74:18-24
pubmed: 34619457
Cancer Res. 2018 Jan 1;78(1):115-128
pubmed: 29066514
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92
pubmed: 18818309
Cell Mol Immunol. 2022 Jan;19(1):23-32
pubmed: 34385592
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Oncoimmunology. 2022 Jan 2;11(1):2012961
pubmed: 36524209
Eur J Immunol. 2021 Mar;51(3):544-556
pubmed: 33450785